분자유전학실험실 (단국대학교 분자생물학과)



 이성욱 ( 2015-01-07 01:05:18 , Hit : 1180
 Janssen, Isis Pharma Ink Up-to-$835M Antisense Agreement


GEN News Highlights
More »
Jan 5, 2015

Johnson & Johnson’s Janssen Biotech will use Isis Pharmaceuticals’ RNA-targeted technology platform to discover and develop antisense drugs to treat autoimmune disorders of the gastrointestinal (GI) tract, in a partnership that could generate up to $835 million for Isis.

The collaboration will also bring Isis Pharma access to Janssen’s expertise in autoimmune disorders and therapeutic formulation toward development of antisense drugs to treat autoimmune disorders in the GI tract through oral delivery and other forms of local administration.

Janssen’s expertise includes its already-marketed intravenous drug Remicade (infliximab), a tumor necrosis factor (TNF) inhibitor that is indicated for a variety of disorders—including Crohn’s disease in children and adults, ulcerative colitis in children and adults, rheumatoid and psoriatic arthritis, ankylosing spondylitis, and plaque psoriasis.

Remicade is a blockbuster for Janssen and parent Johnson & Johnson. During the first nine months of 2014, Remicade racked up $5.196 billion in sales, up 4.7% from Q1-Q3 2013.

“This collaboration broadens the utility of our drug discovery technology to new targets in the GI tract and expands the administration of antisense drugs to local delivery, including oral delivery, to the gut," B. Lynne Parshall, Isis Pharma’s COO, said in a statement.

The collaboration agreement covers three development programs. Janssen agreed to pay Isis Pharma $35 million upfront, including a payment to initiate human lead optimization on the first collaboration target.

Isis Pharma said it is eligible for another nearly $800 million in development, regulatory, and sales milestone payments, as well as license fees for these programs. Isis will also receive tiered royalties averaging double-digits on sales from any product that is successfully commercialized.

In return, Janssen has the option to license a drug from each of the programs once a development candidate is identified. If Janssen exercises its option, it will assume global development, regulatory, and commercialization responsibilities, Isis Pharma said.

Antisense drugs are small (12-21 nucleotides) DNA- or RNA-like compounds that are chemically modified to engineer favorable drug properties. Isis Pharma’s platform is designed to develop antisense drugs that interact precisely with their targets, namely specific sequences of RNA. According to Isis, many of the antisense drugs in its pipeline bind to messenger RNAs (mRNAs), and inhibit the production of disease-causing proteins.

The collaboration aims to expand Isis Pharma’s pipeline, now consisting of 34 drugs for treating  a variety of diseases within its key therapeutic areas of cardiovascular, metabolic, severe and rare diseases, including neurological disorders, and cancer. Isis’ lead product—Kynamro, for treatment of patients with homozygous FH—is being commercialized in the U.S. and other countries through the Sanofi subsidiary Genzyme.

Isis Pharma’s collaboration with Janssen comes less than two months after the company agreed to expand its nearly two-year-old research collaboration with AstraZeneca by launching a strategic alliance to discover and develop new delivery methods for antisense oligonucleotides. The value of that expanded collaboration was not disclosed.








1007   US pharmacy deals could cut costs of AbbVie and Gilead's HCV treatments  이성욱 2015/01/08 1664
  Janssen, Isis Pharma Ink Up-to-$835M Antisense Agreement  이성욱 2015/01/07 1180
1005   CVS Gives Preferred Status to Gilead’s Hepatitis C Drugs  이성욱 2015/01/07 1304
1004   Mass. developer of messenger RNA drugs gets $450M funding boost  이성욱 2015/01/07 966
1003   아직도 풀리지 않은 STAP줄기세포 미스터리  이성욱 2015/01/06 1009
1002   에볼라 확산원인에 대한 새로운 주장  이성욱 2015/01/06 1113
1001   Scientists explain how stem cells and 'bad luck' cause cancer  이성욱 2015/01/06 926
1000   자가 항체에 의한 전신 홍반성 루프스 발생 기작  이성욱 2015/01/05 1551
999   줄기세포로 만든 초기 난자와 정자  이성욱 2014/12/31 1147
998   텔로머레이즈 기반 유전자 요법으로 심장마비 치료  이성욱 2014/12/24 1663
997   일본의 검증팀 STAP 세포 재현 포기, 오보카타 사임  이성욱 2014/12/23 1074
996   아수라장 속에서 탄생한 생명  이성욱 2014/12/17 1237
995   암 생존율을 높일 수 있는 면역세포  이성욱 2014/12/16 1091
994   FDA approves 9-valent HPV vaccine for certain cancers  이성욱 2014/12/12 1142
993   C형 간염 치료에서 비용 효율성을 보인 시메프레비르(simeprevir) 기반 요법  이성욱 2014/12/11 1712
992   Y 염색체 상실을 초래할 수 있는 흡연  이성욱 2014/12/10 1339
991   술의 역사: 영장류가 진화한 것은 알코올 섭취능력 때문?  이성욱 2014/12/04 1267
990   혈우병 환자들에게 안전성과 효과를 입증한 유전자 요법  이성욱 2014/11/27 1614
989   EMA panel recommends approval of DAA regimen for patients with HCV  이성욱 2014/11/26 1282
988   AMD를 치료하는데 사용될 수 있는 HIV/AIDS 약물들  이성욱 2014/11/26 1391

[이전 10개] [1]..[11][12][13] 14 [15][16][17][18][19][20]..[64] [다음 10개]
 

Copyright 1999-2021 Zeroboard / skin by ROBIN